BridgeMD
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
EU CTIS ID: 2023-507655-30-00
What this study is testing
1. To demonstrate that tirzepatide MTD is superior to placebo for achieving BMI reduction. 2. To demonstrate that tirzepatide MTD is superior to placebo for improvement in weight-related comorbidities.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Be 12 to 17 years
- Have a BMI equal to or above the 95th percentile for age and sex on CDC-NCHS 2022
You likely can't join if
- Have Type 1 Diabetes
- Have Type 2 Diabetes
- Have had or plan to have a surgical treatment for obesity
- Have history of an inflamed pancreas (pancreatitis)
The study team makes the final eligibility decision.
Where it's taking place
- Israel
- United Kingdom
- Taiwan
- Mexico
- Australia
- Argentina
- United States
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Israel; United Kingdom; Taiwan; Mexico; Australia; Argentina and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.